BLA Submitted for Ocriplasmin for Symptomatic Vitreomacular Adhesion

ThromboGenics announced that is has submitted a Biologics License Application (BLA) to the FDA for ocriplasmin intravitreal injection 2.5mg/mL for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole. The BLA submission includes data from two pivotal Phase 3 trials involving 652 patients in the US and Europe.

Ocriplasmin (microplasmin) is a truncated form of the human serine protease plasmin that retains its enzymatic properties and is believed to primarily target the fibronectin, laminin, and type IV collagen fibers that adhere the vitreous to the retina.

For more information call (212) 201-0920 or visit www.thrombogenics.com.